Granata Bio
Duxbury, US · Founded 2020 · Delaware corporation · 18 employees on LinkedIn · 4 known investors
Granata Bio is a US-based biopharmaceutical company focused on reproductive health and fertility, in-licensing IVF medications used outside the US to develop and commercialize them in North America. Its aim is to expand therapeutic options, lower costs, and increase access to fertility treatment for patients.
Also known as Granata Bio
Founders & leadership
Granata Bio was founded in 2020 by Evan Sussman, Marc Chung, Sarah Faranda, Dave Paller, and David Paller.
Board
Investors · 4
Reported raises · per SEC filings
Form D private placements$23.9M disclosed across 2 rounds · 2023–2024
▶$13.8MraisedDec 2024 · 3 investors · BiotechnologyRule 506(b)
- EVAN SUSSMANExecutive Officer, Director
- SARAH FARANDAExecutive Officer, Director
- EDUARDO HARITONDirector
- DAVID PALLERExecutive Officer, Director
- PETER TUREKDirector
- Offering amount
- $15M
- Amount sold
- $13.8M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$10.1MraisedNov 2023 · 10 investors · BiotechnologyRule 506(b)
- SARAH FARANDAExecutive Officer, Director
- EVAN SUSSMANExecutive Officer, Director
- EDUARDO HARITONDirector
- DAVID PALLERExecutive Officer, Director
- Offering amount
- $14M
- Amount sold
- $10.1M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Granata Bio is a reproductive health biopharmaceutical company that identifies and evaluates biopharmaceutical candidates with the potential to affect reproductive health in North America. For products it takes forward, the company designs development programs intended to evaluate safety and efficacy, satisfy regulatory requirements, and integrate into modern fertility clinical practice.
The company's therapeutic focus spans the IVF medication continuum, from ovarian stimulation through luteal phase support, and it characterizes the US IVF medication market as undersaturated. Granata Bio is running the Phase III GRACE study, for which it reported initial pregnancies in May 2026 and completion of Cohort A enrollment in July 2026. Company staff have publicly discussed regulatory strategy for complex products and the emerging therapeutic potential of anti-Mullerian hormone (AMH) across menopause, oncofertility and IVF stimulation.
Granata Bio also engages with the patient community, describing itself as a supporter of RESOLVE: The National Infertility Association and other patient advocacy organizations.
Business model
Granata Bio identifies and diligences biopharmaceutical products with potential application in reproductive health, then designs and runs development programs intended to establish safety and efficacy, meet regulatory requirements, and fit into contemporary fertility clinical practice in North America, with commercialization of the resulting therapeutics.
Traction
Granata Bio's Phase III GRACE study reported initial pregnancies in May 2026 and completed Cohort A enrollment in July 2026.
Latest developments
In December 2025 the company published an ASRM-related spotlight on the expanding therapeutic potential of AMH. In January 2026 its Chief Regulatory Officer, CMC, Zeb Younes, was featured in Regulatory Rapporteur, and Granata Bio was featured with David Pepin, PhD, and Oviva Therapeutics in a Time magazine series on longevity. In April 2026 embryologist Thomas "Rusty" Pool discussed the evolution of embryology with Inside Reproductive Health in a piece carried by the company. In May 2026 Granata Bio announced initial pregnancies in the GRACE study, and in July 2026 it announced completion of Cohort A enrollment in the Phase III GRACE study.
▸Full profile — market position, go-to-market, geography
Market position
The company positions itself as addressing what it describes as an undersaturated US IVF medication market, focusing on introducing and optimizing therapeutics across the treatment cycle from ovarian stimulation to luteal phase support.
The company points to a team with more than 130 years of combined reproductive health experience, including expertise in clinical development, regulatory requirements specific to reproductive health products, and commercialization, along with a network of stakeholders in the fertility field.
Go-to-market
Fertility and IVF clinical practices and their patients in North America.
Geography
Granata Bio's stated commercial and development focus is North America, including the US IVF medication market.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 4
by search overlap
Companies competing with Granata Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 5
launches, deals, and filingsGranata Bio announced completion of enrollment for Cohort A of its Phase III GRACE study.
Granata Bio announced the first pregnancies achieved in its GRACE clinical study.
Zeb Younes, Chief Regulatory Officer, CMC at Granata Bio, was featured in the January 2026 issue of Regulatory Rapporteur discussing confidence-based, risk-proportionate regulatory pathways for complex products.
Granata Bio was featured alongside David Pepin, PhD, and Oviva Therapeutics in a Time magazine series on The Age of Longevity.
The company highlighted emerging research positioning anti-Mullerian hormone (AMH) as an addressable therapeutic target with potential applications in menopause, oncofertility and IVF stimulation.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
▸Research sources · 1
primary sources listed
- Granata Biogranata.bio · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Granata Bio do?
- Reproductive health biopharmaceutical company developing and commercializing IVF therapeutics for the North American market.
- Who founded Granata Bio?
- Granata Bio was founded by Evan Sussman, Marc Chung, Sarah Faranda, Dave Paller, David Paller in 2020.
- Who are Granata Bio's investors?
- Granata Bio's investors include Amboy Street Ventures, Strawberry Creek Ventures, Alumni Ventures, GV (Google Ventures).
- How much funding has Granata Bio raised?
- Granata Bio has disclosed $23.9M raised across 2 rounds.
- Where is Granata Bio headquartered?
- Granata Bio is headquartered in Duxbury, US.